It will grow to $9.02 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save ...

Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...

Many SMA patients continue to see gains in motor function with long-term Spinraza treatment, a real-world study from ...

Spinal Muscular Atrophy treatment is evolving fast, with gene therapy, oral drugs, and next-gen muscle enhancers offering new hope and long-term outcomes. With each breakthrough in SMA treatment, we ...

Spinal muscular atrophy (SMA), a #geneticdisorder caused by a lack of survival motor neuron protein, affects about 1 in every 11,000 births in the United States. #pregnancy #medindia ’ Advertisement ...

So far, the child’s lack of symptoms comes as a successful result of the orally administered drug risdiplam, developed by pharmaceutical company Roche, based in Basel, Switzerland. Risdiplam works by ...

SMA is caused by a lack of survival motor neuron protein and occurs in around 1 in every 11,000 births in the United States. If not treated, SMA type 1 (SMA-1), the most common and severe form ...